A mechanism for improved talc pleurodesis via foam delivery.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: England NLM ID: 9417471 Publication Model: Print Cited Medium: Internet ISSN: 1521-0464 (Electronic) Linking ISSN: 10717544 NLM ISO Abbreviation: Drug Deliv Subsets: MEDLINE
    • Publication Information:
      Publication: 2015->: Abingdon, Oxford : Taylor & Francis
      Original Publication: Orlando, FL : Academic Press, c1993-
    • Subject Terms:
      Hydrogels/*chemistry ; Pleurodesis/*methods ; Talc/*administration & dosage; Animals ; Chemistry, Pharmaceutical ; Drug Stability ; Rabbits ; Rheology ; Talc/therapeutic use
    • Abstract:
      Talcum powder is recognized as the leading drug for pleurodesis, a treatment of choice for malignant pleural effusions. Recently, it was shown that hydrogel foam delivery systems significantly enhanced the number of adhesions between the chest wall and the lung in a New Zealand rabbit model due to the sol-gel transition. However, many questions still remain regarding the cause of improved efficacy, such as: (1) Would only hydrogel foams improve the efficacy of talc pleurodesis? (2) Is it possible to achieve the same efficacy of hydrogels using non-hydrogel foams? 3) What are the physicochemical properties that can be correlated to the efficacy of talc pleurodesis? In this study, we use non-hydrogel foam formulations to determine the efficacy of pleurodesis. Foam stability and rheology of the formulations were correlated to adhesion formation. The results clearly suggest a correlation of pleurodesis efficacy to the viscosity and modulus of the foam delivery system.
    • References:
      J Cardiothorac Surg. 2020 Apr 15;15(1):58. (PMID: 32295636)
      Respir Res. 2019 Nov 7;20(1):247. (PMID: 31699094)
      Chest. 1994 Aug;106(2):342-6. (PMID: 7774299)
      Eur Respir J. 1997 Jul;10(7):1648-54. (PMID: 9230261)
      Respir Med. 2009 Jan;103(1):91-7. (PMID: 18789662)
      Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1441-4. (PMID: 9603121)
      Dermatol Surg. 2001 Jan;27(1):58-60. (PMID: 11231246)
      Ann Thorac Surg. 1976 Jul;22(1):8-15. (PMID: 938141)
      BMC Cancer. 2019 Jun 24;19(1):614. (PMID: 31234819)
      JAMA. 2020 Jan 7;323(1):60-69. (PMID: 31804680)
      Lung Cancer. 2006 Oct;54(1):1-9. (PMID: 16893591)
      Cochrane Database Syst Rev. 2004;(1):CD002916. (PMID: 14973997)
      Ann Intern Med. 1994 Jan 1;120(1):56-64. (PMID: 8250457)
      Chest. 2001 Mar;119(3):801-6. (PMID: 11243960)
    • Grant Information:
      R43 CA210696 United States CA NCI NIH HHS
    • Contributed Indexing:
      Keywords: Drug delivery; foam; malignant pleural effusions; pleurodesis; rheology
    • Accession Number:
      0 (Hydrogels)
      14807-96-6 (Talc)
    • Publication Date:
      Date Created: 20210408 Date Completed: 20211104 Latest Revision: 20220716
    • Publication Date:
      20240104
    • Accession Number:
      PMC8043610
    • Accession Number:
      10.1080/10717544.2021.1895910
    • Accession Number:
      33827326